Delivery Order SPE2DB22D3011-SPE2DB24FQ3NS

Award Date 8/29/24
Potential Completion Date 8/30/24
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $15,866.68 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product, with a period of performance through June 10, 2024. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $14,903.68 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the delivery of 4564015152 CEFEPIME-DEXTROSE 2 GM/50 MLS, a pharmaceutical product, to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 and...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,072,289 units of the pharmaceutical product Cefepime-Dextrose 2 gm/50 mL. The delivery order, valued at $3,653.65, has an ultimate completion date of March 26, 2024. Amerisourcebergen Drug Corp is the prime contractor on an Indefinite Delivery Contract (IDC) with DLA valued up to $999,999,999.00...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,187.46 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of 4564452251 - CEFAZOLIN 2 G/50 ML-DEXTROSES, a pharmaceutical product. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 with DLA Troop Support Medical through December 31, 2025, which serves as the primary...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,863.71 firm fixed-price contract covers the delivery of the pharmaceutical product CEFEPIME-DEXTROSE 2 GM/50 MLS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and...
The U.S. Defense Logistics Agency (DLA) has awarded a firm-fixed-price delivery order contract worth $2,374.92 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of 4564782841 CEFAZOLIN 2 G/50 ML-DEXTROSES, a pharmaceutical product, with a period of performance through June 4, 2024. This delivery order is made under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,023.24, is a delivery order for the supply of 4563866018 - CEFEPIME-DEXTROSE 2 GM/50 MLS, with a performance period ending on March 6, 2024. The contract is a firm fixed-price agreement and was not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,717.32, is for the delivery of Cefepime-Dextrose 2 GM/50 MLS, a pharmaceutical product, with a performance period ending on January 25, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,211,439 units of the drug Cefepime-Dextrose 2 grams/50 mL. The firm-fixed-price delivery order has a ceiling value of $14,774.54 and a completion date of October 28, 2024. The contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award, valued at $3,616.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the medical product "CEFEPIME-DEXTROSE 2 GM/50 MLS" and has an ultimate completion date of November 8, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB24FQ3NS
    Delivery Order

The Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order valued at $2,571.23 to AmerisourceBergen Drug Corporation's Corporate Office division. The order is for the supply of 4,565,632,410 units of the pharmaceutical product CEFEPIME-DEXTROSE 2 GM/50 MLS. This delivery order falls under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at up to $999,999,999 through December 2025, for providing a wide range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation, and the ultimate completion date is August 30, 2024.

Generated 11/28/24, 9:33 AM